Trevi Therapeutics, Inc. Announces Resignation of Eran Nadav as Member of the Board of Directors
January 06, 2020 at 04:07 pm
Share
Trevi Therapeutics, Inc. announced that Eran Nadav, Ph.D. resigned from his position as a member of the Board of Directors. Dr. Nadav’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
TREVI THERAPEUTICS, INC. 
